Barclays Sees Reinforced Long-Term Growth Narrative for Eli Lilly and Company (LLY)

We recently compiled a list of the 10 Best Cancer Stocks to Buy for the Long Term. Eli Lilly and Company is one of the best cancer stocks.

TheFly reported on May 5 that Barclays increased its valuation outlook for LLY, raising the price target to $1,400 from $1,350 while maintaining an Overweight rating. The adjustment followed the company’s first-quarter earnings update, which led to higher estimates. The firm highlighted that strong ongoing demand for tirzepatide is reinforcing investor attention on the company’s broader long-term growth narrative, shifting focus back to its core pipeline strength and market positioning after the recent results.

In a separate development, on May 6, Eli Lilly and Company (NYSE:LLY) announced an additional $4.5 billion investment across two of its manufacturing sites in Lebanon, Indiana, expanding its long-term capital commitment in the state to more than $21 billion since 2020. The decision was driven by expected growth in demand for its medicines and continued expansion of its pipeline.

Barclays Sees Reinforced Long-Term Growth Narrative for Eli Lilly and Company (NYSE:LLY)

The funding will support advanced production capabilities, including updated manufacturing technologies at its active pharmaceutical ingredient facility and the development of its dedicated genetic medicine production site. This expansion reflects the company’s ongoing efforts to strengthen its U.S.-based manufacturing and support future therapeutic development.

Eli Lilly and Company (NYSE:LLY) is a global pharmaceutical company based in Indianapolis that is expanding its oncology portfolio. Alongside its strong diabetes and obesity business, it is growing in precision cancer therapies for breast, lung, and blood cancers through strategic acquisitions and development programs.

While we acknowledge the risk and potential of LLY as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than LLY and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: Top 10 AI-Powered Biotech Stocks to Buy Right Now  and 9 Most Undervalued Healthcare Stocks to Buy Now.

Disclosure: None. Follow Insider Monkey on Google News.